Solstice Oncology
Tracked across 1 events · 6 articles · First seen Sep 09, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Solstice Oncology, a clinical-stage immuno-oncology company focused on neoadjuvant cancer treatment, launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion Ventures and other investors. The…
Impact: Solstice Oncology launched with a $225 million Series A financing and is advancing porustobart into a Phase 2 neoadjuvant colon cancer trial, positioning it as a well-funded clinical-stage immuno-oncology company.
Sep 09, 2026 · 6 articles
95
Solstice Oncology launched with Series A financingSolstice Oncology $225M...
85
Solstice Oncology advanced porustobart into Phase 2Solstice Oncology $225M...
85
Harbour BioMed licensed porustobart Solstice OncologySolstice Oncology $225M...
80
RA Capital Management led Series A financing Solstice OncologySolstice Oncology $225M...
60
Canaan Partners participated in Series A financing Solstice OncologySolstice Oncology $225M...
60
Forbion Ventures participated in Series A financing Solstice OncologySolstice Oncology $225M...
ERGEN INTELLIGENCE
Track Solstice Oncology live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard